CrossBridge Bio is a biotechnology company focused on innovating ADC Therapeutics through stable dual-linker payload technology.
Mentions in press and media 4
| Date | Title | Description |
| 09.11.2024 | CrossBridge Bio Secures $10 Million to Revolutionize Cancer Treatment | In the heart of Houston, a biotechnology company is making waves. CrossBridge Bio has raised $10 million in seed funding to advance its innovative approach to cancer treatment. This funding round, led by TMC Venture Fund and CE-Ventures, si... |
| 08.11.2024 | CrossBridge Bio: $10 Million (Seed) Raised To Advance Antibody-Drug Conjugates As Targeted Cancer Therapies | CrossBridge Bio, a biotechnology company focused on dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, announced the closing of a $10 million seed financing led by TMC Venture Fund and CE-Ventures (the corporate vent... |
| 05.11.2024 | CrossBridge Bio Raises $10M in Funding | CrossBridge Bio, a Houston, TX-based biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, raised $10M in funding. The round was led by TMC Venture Fund and CE-Ventures, with participati... |
| - | CrossBridge Bio | “CrossBridge Bio is a biotechnology company focused on innovating ADC Therapeutics through stable dual-linker payload technology.” |